Atte Meretoja

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/685664/publications.pdf

Version: 2024-02-01

132 papers	67,430 citations	20817 60 h-index	13379 130 g-index
134 all docs	134 docs citations	134 times ranked	95928 citing authors

#	Article	IF	Citations
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
3	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
4	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
5	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
6	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
7	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
8	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	2.8	2,705
9	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
10	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	10.2	2,005
11	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
12	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
13	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
14	Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	10.2	1,521
15	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	10.2	1,512
16	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
17	Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology, 2015, 45, 161-176.	2.3	1,002
18	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 2018, 379, 2429-2437.	27.0	959

#	Article	IF	Citations
19	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740
20	Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. New England Journal of Medicine, 2019, 380, 1795-1803.	27.0	653
21	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
22	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	13.7	609
23	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
24	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
25	Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology, 2012, 79, 306-313.	1.1	490
26	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
27	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
28	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
29	Extending thrombolysis to 4Â·5â€“9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet, The, 2019, 394, 139-147.	13.7	321
30	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
31	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995â€“2050. Lancet, The, 2019, 393, 2233-2260.	13.7	283
32	The Burden of Cardiovascular Diseases Among US States, 1990-2016. JAMA Cardiology, 2018, 3, 375.	6.1	271
33	Stroke Thrombolysis. Stroke, 2014, 45, 1053-1058.	2.0	270
34	SMASH-U. Stroke, 2012, 43, 2592-2597.	2.0	252
35	Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology, 2013, 81, 1071-1076.	1.1	242
36	Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score. Annals of Neurology, 2012, 71, 634-641.	5.3	233

#	Article	IF	Citations
37	Predicting outcome of IV thrombolysisâ€“treated ischemic stroke patients. Neurology, 2012, 78, 427-432.	1.1	216
38	Evolution and patterns of global health financing 1995â€“2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet, The, 2017, 389, 1981-2004.	13.7	204
39	Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke. Stroke, 2010, 41, 1450-1458.	2.0	195
40	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016â€“40. Lancet, The, 2018, 391, 1783-1798.	13.7	172
41	Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology, 2011, 77, 341-348.	1.1	167
42	Future and potential spending on health 2015â€“40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet, The, 2017, 389, 2005-2030.	13.7	163
43	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
44	The CAVE Score for Predicting Late Seizures After Intracerebral Hemorrhage. Stroke, 2014, 45, 1971-1976.	2.0	152
45	Effectiveness of Primary and Comprehensive Stroke Centers. Stroke, 2010, 41, 1102-1107.	2.0	129
46	Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995â€“2015. Lancet, The, 2018, 391, 1799-1829.	13.7	127
47	Endovascular therapy for ischemic stroke. Neurology, 2017, 88, 2123-2127.	1.1	124
48	Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology, 2017, 88, 1693-1700.	1.1	121
49	Mild Hypothermia After Intravenous Thrombolysis in Patients With Acute Stroke. Stroke, 2014, 45, 486-491.	2.0	106
50	Thrombolysis in Stroke Despite Contraindications or Warnings?. Stroke, 2013, 44, 727-733.	2.0	102
51	Imaging Selection in Ischemic Stroke: Feasibility of Automated CT-Perfusion Analysis. International Journal of Stroke, 2015, 10, 51-54.	5.9	100
52	National stroke registries for monitoring and improving the quality of hospital care: A systematic review. International Journal of Stroke, 2016, 11, 28-40.	5.9	96
53	Natural History of Perihematomal Edema and Impact on Outcome After Intracerebral Hemorrhage. Stroke, 2017, 48, 873-879.	2.0	93
54	Epidemiology of hereditary neuropathy with liability to pressure palsies (HNPP) in south western Finland. Neuromuscular Disorders, 1997, 7, 529-532.	0.6	92

#	Article	IF	Citations
55	Outcome by Stroke Etiology in Patients Receiving Thrombolytic Treatment. Stroke, 2011, 42, 102-106.	2.0	88
56	Reversal strategies for vitamin <scp>K</scp> antagonists in acute intracerebral hemorrhage. Annals of Neurology, 2015, 78, 54-62.	5.3	87
57	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Lancet, The, 2020, 396, 693-724.	13.7	87
58	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990â€“2050. Lancet, The, 2021, 398, 1317-1343.	13.7	79
59	Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2020, 19, 980-987.	10.2	70
60	Stroke Mimics and Intravenous Thrombolysis. Annals of Emergency Medicine, 2012, 59, 27-32.	0.6	64
61	The Spot Sign and Tranexamic Acid on Preventing ICH Growth â€“ AUStralasia Trial (STOP-AUST): Protocol of a Phase II Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. International Journal of Stroke, 2014, 9, 519-524.	5.9	62
62	Symptomatic Intracranial Hemorrhage After Stroke Thrombolysis. Stroke, 2014, 45, 752-758.	2.0	61
63	Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet Public Health, The, 2019, 4, e658-e669.	10.0	56
64	Cerebral Edema in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis. International Journal of Stroke, 2013, 8, 529-534.	5.9	55
65	Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability. Stroke, 2015, 46, 2341-2346.	2.0	54
66	Stroke Monitoring on a National Level. Stroke, 2010, 41, 2239-2246.	2.0	53
67	Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost. Frontiers in Neurology, 2017, 8, 657.	2.4	53
68	Incidence, risk factors, etiology, severity and shortâ€term outcome of nonâ€traumatic intracerebral hemorrhage in young adults. European Journal of Neurology, 2015, 22, 123-132.	3.3	52
69	Association of Prestroke Statin Use and Lipid Levels With Outcome of Intracerebral Hemorrhage. Stroke, 2013, 44, 2330-2332.	2.0	50
70	Pre-Stroke CHADS₂ and CHA₂DS₂-VASc Scores Are Useful in Stratifying Three-Month Outcomes in Patients with and without Atrial Fibrillation. Cerebrovascular Diseases, 2013, 36, 273-280.	1.7	49
71	Do-Not-Resuscitate (DNR) Orders in Patients with Intracerebral Hemorrhage. International Journal of Stroke, 2014, 9, 53-58.	5.9	48
72	Reliability of intracerebral hemorrhage classification systems: A systematic review. International Journal of Stroke, 2016, 11, 626-636.	5.9	46

#	Article	IF	Citations
73	Neuroimaging and clinical outcomes of oral anticoagulantâ€“associated intracerebral hemorrhage. Annals of Neurology, 2018, 84, 694-704.	5.3	46
74	Post-Thrombolytic Hyperglycemia and 3-Month Outcome in Acute Ischemic Stroke. Cerebrovascular Diseases, 2011, 31, 83-92.	1.7	44
75	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
76	Comparison of all 19 published prognostic scores for intracerebral hemorrhage. Journal of the Neurological Sciences, 2017, 379, 103-108.	0.6	43
77	Does Time of Day Or Physician Experience Affect Outcome of Acute Ischemic Stroke Patients Treated with Thrombolysis? a Study from Finland. International Journal of Stroke, 2012, 7, 511-516.	5.9	41
78	Validation of the DRAGON Score in 12 Stroke Centers in Anterior and Posterior Circulation. Stroke, 2013, 44, 2718-2721.	2.0	41
79	Trends in treatment and outcome of stroke patients in Finland from 1999 to 2007. PERFECT Stroke, a nationwide register study. Annals of Medicine, 2011, 43, S22-S30.	3.8	40
80	In-Hospital Cardiac Complications after Intracerebral Hemorrhage. International Journal of Stroke, 2014, 9, 741-746.	5.9	39
81	Comparing ischaemic stroke in six European countries. The Euro<scp>HOPE</scp> register study. European Journal of Neurology, 2015, 22, 284.	3.3	39
82	Stroke Thrombolysis in a Centralized and a Decentralized System (Helsinki and Telemedical Project for) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.0	38
83	Direct Costs of Patients With Stroke Can Be Continuously Monitored on a National Level. Stroke, 2011, 42, 2007-2012.	2.0	36
84	Persistent Hyperglycemia Is Associated With Increased Mortality After Intracerebral Hemorrhage. Journal of the American Heart Association, 2017, 6, .	3.7	34
85	Body Temperature, Blood Infection Parameters, and Outcome of Thrombolysis-Treated Ischemic Stroke Patients. International Journal of Stroke, 2013, 8, 632-638.	5.9	33
86	Preâ€•and inâ€hospital intersection of stroke care. Annals of the New York Academy of Sciences, 2012, 1268, 145-151.	3.8	32
87	Predictors of Early Mortality in Young Adults After Intracerebral Hemorrhage. Stroke, 2014, 45, 2454-2456.	2.0	32
88	Extent of Secondary Intraventricular Hemorrhage is an Independent Predictor of Outcomes in Intracerebral Hemorrhage: Data from the Helsinki ICH Study. International Journal of Stroke, 2015, 10, 576-581.	5.9	32
89	Undetermined stroke with an embolic patternâ€”a common phenotype with high early recurrence risk. Annals of Medicine, 2015, 47, 406-413.	3.8	32
90	Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiology and Drug Safety, 2016, 25, 161-169.	1.9	31

#	Article	IF	Citations
91	Higher baseline international normalized ratio value correlates with higher mortality in intracerebral hemorrhage during warfarin use. European Journal of Neurology, 2014, 21, 616-622.	3.3	30
92	Development of a Non-invasive Device for Swallow Screening in Patients at Risk of Oropharyngeal Dysphagia: Results from a Prospective Exploratory Study. Dysphagia, 2019, 34, 698-707.	1.8	30
93	Intravenous Thrombolysis for Acute Ischemic Stroke Patients Presenting with Mild Symptoms. International Journal of Stroke, 2013, 8, 293-299.	5.9	28
94	Simultaneous Multiple Intracerebral Hemorrhages (SMICH). Stroke, 2017, 48, 581-586.	2.0	26
95	Three-month modified Rankin Scale as a determinant of 5-year cumulative costs after ischemic stroke. Neurology, 2020, 94, e978-e991.	1.1	26
96	Multicenter Accuracy and Interobserver Agreement of Spot Sign Identification in Acute Intracerebral Hemorrhage. Stroke, 2014, 45, 107-112.	2.0	24
97	Male predominance in disease severity and mortality in a low Covid-19 epidemic and low case-fatality area â€“ a population-based registry study. Infectious Diseases, 2021, 53, 789-799.	2.8	24
98	Helsinki Stroke Model Is Transferrable With â€œReal-Worldâ€•Resources and Reduced Stroke Thrombolysis Delay to 34â€‰min in Christchurch. Frontiers in Neurology, 2018, 9, 290.	2.4	23
99	Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location. Journal of the Neurological Sciences, 2013, 332, 75-79.	0.6	22
100	Outcome After Clipping and Coiling for Aneurysmal Subarachnoid Hemorrhage in Clinical Practice in Europe, USA, and Australia. Neurosurgery, 2019, 84, 1019-1027.	1.1	21
101	Software output from semi-automated planimetry can underestimate intracerebral haemorrhage and peri-haematomal oedema volumes by up to 41Â%. Neuroradiology, 2016, 58, 867-876.	2.2	20
102	Treatment of intracerebral haemorrhage with tranexamic acid â€“ A review of current evidence and ongoing trials. European Stroke Journal, 2017, 2, 13-22.	5.5	18
103	Diabetes and intracerebral hemorrhage: baseline characteristics and mortality. European Journal of Neurology, 2018, 25, 825-832.	3.3	18
104	Novel Thrombolytic Drugs. CNS Drugs, 2008, 22, 619-629.	5.9	15
105	Elevated urea level is associated with poor clinical outcome and increased mortality post intravenous tissue plasminogen activator in stroke patients. Journal of the Neurological Sciences, 2013, 332, 110-115.	0.6	15
106	Stroke doctors: Who are we? A World Stroke Organization survey. International Journal of Stroke, 2017, 12, 858-868.	5.9	15
107	Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2018, 65, 489-517.	2.6	14
108	Antipsychotic Use Among 1144 Patients After Aneurysmal Subarachnoid Hemorrhage. Stroke, 2019, 50, 1711-1718.	2.0	14

#	Article	IF	Citations
109	Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group. European Stroke Journal, 2020, 5, 184-192.	5.5	13
110	Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts. Current Vascular Pharmacology, 2006, 4, 31-44.	1.7	12
111	Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial. Stroke and Vascular Neurology, 2022, 7, 158-165.	3.3	12
112	Evolution of Intracerebral Hemorrhage after Intravenous Tpa: Reversal of Harmful Effects with Mast Cell Stabilization. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 176-181.	4.3	11
113	Hospital case-volume is associated with case-fatality after aneurysmal subarachnoid hemorrhage. International Journal of Stroke, 2019, 14, 282-289.	5.9	11
114	Lost potential of kidney and liver donors amongst deceased intracerebral hemorrhage patients. European Journal of Neurology, 2014, 21, 153-159.	3.3	9
115	Trends and Predictors of Oral Anticoagulant Use in People with Alzheimerâ€™s Disease and the General Population in Australia. Journal of Alzheimer's Disease, 2019, 70, 733-745.	2.6	9
116	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Archives of Public Health, 2022, 80, 142.	2.4	9
117	Treatment of intracerebellar haemorrhage: Poor outcome and high long-term mortality. , 2017, 8, 272.		8
118	Validation of a decision support model for investigation and improvement in stroke thrombolysis. European Journal of Operational Research, 2016, 253, 154-169.	5.7	7
119	Impact of pre-stroke sulphonylurea and metformin use on mortality of intracerebral haemorrhage. European Stroke Journal, 2016, 1, 302-309.	5.5	7
120	Effect of baseline hypocalcaemia on volume of intracerebral haemorrhage in patients presenting within 72 hours from symptom onset. Journal of the Neurological Sciences, 2019, 403, 24-29.	0.6	7
121	Airplane stroke syndrome. Journal of Clinical Neuroscience, 2016, 29, 77-80.	1.5	6
122	Beta-blocker therapy is not associated with mortality after intracerebral hemorrhage. Acta Neurologica Scandinavica, 2018, 137, 105-108.	2.1	6
123	Does variability in automated perfusion software outputs for acute ischemic stroke matter? Reanalysis of EXTEND perfusion imaging. CNS Neuroscience and Therapeutics, 2022, 28, 139-144.	3.9	6
124	Hemiplegia and thrombolysis. European Journal of Neurology, 2012, 19, 1235-1238.	3.3	5
125	Changes in acute hospital costs after employing clinical facilitators to improve stroke care in Victoria, Australia. BMC Health Services Research, 2019, 19, 41.	2.2	5
126	Outcome of ischemic stroke patients with serious post-thrombolysis neurological deficits. Acta Neurologica Scandinavica, 2013, 127, 221-226.	2.1	4

#	Article	IF	Citations
127	Does tranexamic acid affect intraventricular hemorrhage growth in acute ICH? An analysis of the STOP-AUST trial. European Stroke Journal, 2022, 7, 15-19.	5.5	3
128	Inflammation parameters predict fatal outcome in male COVID-19 patients in a low case-fatality area â€“ a population-based registry study. Infectious Diseases, 2022, 54, 558-571.	2.8	2
129	Reply. Annals of Neurology, 2016, 79, 332-333.	5.3	1
130	Occipital intracerebral hemorrhageâ€”clinical characteristics, outcome, and postâ€ICH epilepsy. Acta Neurologica Scandinavica, 2021, 143, 71-77.	2.1	1
131	Response to Letter by Longstreth and Tirschwell. Stroke, 2010, 41, .	2.0	0
132	Atte Meretoja. International Journal of Stroke, 2016, 11, NP1-NP2.	5.9	0